Iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use

Patent metadata

Field	Value
Publication number	US-9687494-B2
Application number	US-201615250338-A
Country	US
Kind code	B2
Filing date	Aug 29, 2016
Priority date	Oct 8, 2009
Publication date	Jun 27, 2017
Grant date	Jun 27, 2017

Abstract

In its many embodiments, the present invention provides certain iminothiadiazine dioxide compounds, including compounds Formula (I): (I) and include stereoisomers thereof, and pharmaceutically acceptable salts of said compounds stereoisomers, wherein each of R 1 , R 2 , R 3 , R 4 , R 5 , R 9 , ring A, ring B, m, n, p, -L 1 -, L 2 -, and L 3 - is selected independently and as defined herein. The novel iminothiadiazine dioxide compounds of the invention have surprisingly been found to exhibit properties which are expected to render them advantageous as BACE inhibitors and/or for the treatment and prevention of various pathologies related to β-amyloid (Aβ) production. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use in treating pathologies associated with amyloid beta (Aβ) protein, including Alzheimers disease, are also disclosed.

First claim

We claim:

1. A method of treating Alzheimer's disease in a human in need thereof comprising administering to the human a therapeutically effective amount of a compound, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, said compound selected from the group consisting of:

2. A method of treating Alzheimer's disease in a human in need thereof comprising administering to the human a therapeutically effective amount of a compound having a structure:

or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

3. The method of claim 2 , wherein said compound is a compound having a structure:

or a tautomer thereof.

4. The method of claim 3 , wherein said compound is a pharmaceutically salt of a compound having a structure:

or a pharmaceutically acceptable salt of a tautomer thereof, wherein said pharmaceutically acceptable salt is selected from the group consisting of acetate, ascorbate, benzoate, benzenesulfonate, bisulfate, borate, butyrate, citrate, camphorate, camphorsulfonate, fumarate, hydrochloride, hydrobromide, hydroiodide, lactate, maleate, methanesulfonate, naphthalenesulfonate, nitrate, oxalate, phosphate, propionate, salicylate, succinate, sulfate, tartarate, thiocyanate, and toluenesulfonate.

5. The method of claim 4 , wherein said pharmaceutically acceptable salt is a hydrochloride salt.

6. The method of claim 4 , wherein said pharmaceutically acceptable salt is a toluenesulfonate salt.

7. A method of treating mild cognitive impairment in a human in need thereof comprising administering to the human a therapeutically effective amount of a compound, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, said compound selected from the group consisting of:

8. A method of treating mild cognitive impairment in a human in need thereof comprising administering to the human a therapeutically effective amount of a compound having a structure:

or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

9. The method of claim 8 , wherein said compound is a compound having a structure:

or a tautomer thereof.

10. The method of claim 9 , wherein said compound is a pharmaceutically salt of a compound having a structure:

or a pharmaceutically acceptable salt of a tautomer thereof, wherein said pharmaceutically acceptable salt is selected from the group consisting of acetate, ascorbate, benzoate, benzenesulfonate, bisulfate, borate, butyrate, citrate, camphorate, camphorsulfonate, fumarate, hydrochloride, hydrobromide, hydroiodide, lactate, maleate, methanesulfonate, naphthalenesulfonate, nitrate, oxalate, phosphate, propionate, salicylate, succinate, sulfate, tartarate, thiocyanate, and toluenesulfonate.

11. The method of claim 10 , wherein said pharmaceutically acceptable salt is a hydrochloride salt.

12. The method of claim 10 , wherein said pharmaceutically acceptable salt is a toluenesulfonate salt.

13. A method of lowering the production of Aβ 40 in the cerebral cortex of a human in need thereof comprising administering to the human a therapeutically effective amount of a compound, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, said compound selected from the group consisting of:

14. A method of lowering the production of Aβ 40 in the cerebral cortex of a human in need thereof comprising administering to the human a therapeutically effective amount of a compound, having a structure:

or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

15. The method of claim 14 , wherein said compound is a compound having a structure:

or a tautomer thereof.

16. The method of claim 14 , wherein said compound is a pharmaceutically salt of a compound having a structure:

or a pharmaceutically acceptable salt of a tautomer thereof, wherein said pharmaceutically acceptable salt is selected from the group consisting of acetate, ascorbate, benzoate, benzenesulfonate, bisulfate, borate, butyrate, citrate, camphorate, camphorsulfonate, fumarate, hydrochloride, hydrobromide, hydroiodide, lactate, maleate, methanesulfonate, naphthalenesulfonate, nitrate, oxalate, phosphate, propionate, salicylate, succinate, sulfate, tartarate, thiocyanate, and toluenesulfonate.

17. The method of claim 16 , wherein said pharmaceutically acceptable salt is a hydrochloride salt.

18. The method of claim 16 , wherein said pharmaceutically acceptable salt is a toluenesulfonate salt.

19. A method of inhibiting the formation of AP peptides in a human in need thereof, which method comprises administering to the human a therapeutically effective amount of a compound, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein said compound is selected from the group consisting of:

20. A method of inhibiting the formation of Aβ peptides in a human in need thereof comprising administering to the human a therapeutically effective amount of a compound having a structure:

or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

21. The method of claim 20 , wherein said compound is a compound having a structure:

or a tautomer thereof.

22. The method of claim 21 , wherein said compound is a pharmaceutically salt of a compound having a structure:

or a pharmaceutically acceptable salt of a tautomer thereof, wherein said pharmaceutically acceptable salt is selected from the group consisting of acetate, ascorbate, benzoate, benzenesulfonate, bisulfate, borate, butyrate, citrate, camphorate, camphorsulfonate, fumarate, hydrochloride, hydrobromide, hydroiodide, lactate, maleate, methanesulfonate, naphthalenesulfonate, nitr

Assignees

• Merck Sharp & Dohme

Inventors

• Scott Jack D
• Stamford Andrew W
• Gilbert Eric J
• Cumming Jared N
• Iserloh Ulrich

Classifications

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P5/50

  for increasing or potentiating the activity of insulin · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title